Trials / Completed
CompletedNCT02648048
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone | Pirfenidone will be administered as per the dosage schedule mentioned in arm description. |
| DRUG | Vismodegib | Vismodegib will be administered as per the dosage schedule mentioned in arm description. |
Timeline
- Start date
- 2016-01-15
- Primary completion
- 2016-11-30
- Completion
- 2016-11-30
- First posted
- 2016-01-06
- Last updated
- 2017-10-30
Locations
15 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT02648048. Inclusion in this directory is not an endorsement.